体重≥120公斤患者全髋关节置换术中头孢唑林2克与3克预防感染的比较
本研究基于大型国家数据库回顾性比较体重≥120公斤初次全髋关节置换患者接受2克与3克头孢唑林预防的90天假体周围感染率。结果显示两组感染率无显著差异(1.4% vs 1.6%,P=0.17),多变量分析剂量与感染风险无关(OR 1.16,95%CI 0.43-3.07,P=0.77),贝叶斯分析提示3克降低感染风险的概率为87%。
要点
- 体重≥120公斤全髋置换患者中,3克与2克头孢唑林90天假体周围感染率无显著差异。
- 多变量分析显示头孢唑林剂量与感染风险无关(OR 1.16,95%CI 0.43-3.07,P=0.77)。
- 贝叶斯分析显示3克降低感染风险的概率为87%,提示中等但不确切的获益。
核心结论
- 体重≥120公斤全髋关节置换患者中,3克头孢唑林与2克相比未显著降低90天假体周围感染风险。
- 贝叶斯分析提示3克剂量可能降低感染风险的概率为87%,但证据不确切。
- 现有证据不足以推荐改变当前指南,需更大样本研究确定最佳预防剂量。
研究设计与样本
- 回顾性队列研究,使用大型国家数据库。
- 纳入2016年4月至2022年7月期间接受初次全髋关节置换、体重≥120公斤且接受头孢唑林预防的成年患者。
- 按剂量分为2克组与3克组,采用多变量逻辑回归调整年龄、种族、族裔、支付方状态、住院时长和Elixhauser合并症指数评估90天假体周围感染风险,并用贝叶斯后验分析量化不确定性。
主要发现
- 90天假体周围感染率2克组为1.4%,3克组为1.6%,差异无统计学意义(P=0.17)。
- 多变量分析中头孢唑林剂量与感染风险无关(OR 1.16,95%CI 0.43-3.07,P=0.77)。
- 贝叶斯分析显示3克剂量降低感染风险的概率为87%。
临床怎么用
- 对于体重≥120公斤的全髋关节置换患者,当前证据不支持常规将头孢唑林预防剂量从2克改为3克。
- 临床决策时可考虑贝叶斯分析提示的3克可能中等概率获益,但需权衡不确定性。
局限性
- 回顾性研究设计可能存在残余混杂。
- 原文未报告具体样本量及更多局限性细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-body weight total hip arthroplasty (THA) patients face elevated risks for postoperative complications such as periprosthetic joint infection (PJI). Although guidelines recommend three grams of cefazolin for patients weighing greater than 120 kg, supporting evidence is limited and conflicting. This study compared PJI incidence among patients receiving two versus three grams of prophylactic cefazolin. METHODS: A retrospective cohort study was conducted using a large national database. Adult patients weighing greater than or equal to 120 kg who underwent primary THA between April 2016 and July 2022 and received cefazolin prophylaxis were included. Patients were grouped by dose (two versus three grams). A multivariable logistic regression adjusting for age, race, ethnicity, payer status, lengths of stay, and Elixhauser Comorbidity Index assessed 90-days PJI risk. A Bayesian posterior analysis using the same model quantified uncertainty. RESULTS: The 90-day PJI rates did not differ significantly (1.4 versus 1.6%; P = 0.17). On multivariable analysis, cefazolin dose was not associated with PJI risk (odds ratio 1.16; 95% confidence interval 0.43 to 3.07; P = 0.77). Bayesian analysis demonstrated an 87% probability that higher dosing reduced PJI risk, suggesting a moderate, but uncertain benefit. CONCLUSIONS: Among THA patients weighing ≥ 120 kg, three grams of cefazolin was not associated with a statistically significant reduction in PJI risk compared to two grams. However, Bayesian analysis suggested a moderate probability that a three-gram dosing may reduce infection risk. These findings do not provide sufficient evidence to recommend changing current guidelines, but highlight ongoing uncertainty and the need for larger studies to define optimal prophylactic dosing in this population.
引用
- Hurka KL, Rumalla KC, Memon R, et al. Cefazolin Prophylaxis in Patients ≥120 Kilograms: Comparison of Periprosthetic Joint Infection Following Total Hip Arthroplasty With Two Versus Three Grams Dosing. J Arthroplasty. 2026. PMID: 42442436. doi:10.1016/j.arth.2026.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。